Efficacy and safety of sintilimab in the treatment of sqNSCLC

Objective: To investigate the efficacy and safety of sintilimab in the treatment of sqNSCLC. Methodology: This retrospective study enrolled 64 patients with advanced sqNSCLC receiving intervention at the Shijiazhuang People’s Hospital according to the inclusion and exclusion criteria between January, 2022 to December, 2024 and were randomly divided into the observation and control groups, each including 32 patients with advanced sqNSCLC. The patients in the observation group received gemcitabine and sintilimab, as well as gemcitabine plus cisplatin, whereas patients in the control group received sintilimab sequentially with gemcitabine plus cisplatin. Compared to each other to evaluate the efficacy and safety of sintilimab in the treatment of advanced sqNSCLC. Results: After four cycles of treatment, the ORR of the control group patients with advanced sqNSCLC was significantly better than that of the observation group (P< 0.05), and no significant difference was found in the DCR(P> 0.05); however, the control group’s DCR was slightly higher than that of the observation group. During the treatment course, no deaths due to adverse reactions were recorded. The adverse reactions were mainly distributed in Grades-1 and 2; the incidence of adverse reactions in the control group was significantly lower than that in the observation group (P < 0.05). Conclusion: Sintilimab, as a treatment option for advanced sqNSCLC, can safely improve the effectiveness of intervention in advanced sqNSCLC and prolong the survival of patients with sqNSCLC, with a good safety profile.